Yi Jun Ho, Lee Gyeong-Won, Lee Ji Hyun, Yoo Kwai Han, Jung Chul Won, Kim Dae Sik, Lee Jeong-Ok, Eom Hyeon Seok, Byun Ja Min, Koh Youngil, Yoon Sung Soo, Kim Jin Seok, Kong Jee Hyun, Yhim Ho-Young, Yang Deok-Hwan, Yoon Dok Hyun, Lim Do Hyoung, Lee Won-Sik, Shin Ho-Jin
Division of Hematology-Oncology, Department of Medicine, Chung-Ang University Hospital, Seoul, Korea.
Division of Hematology-Oncology, Department of Internal Medicine, Institute of Health Science, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea.
Blood Res. 2021 Dec 31;56(4):243-251. doi: 10.5045/br.2021.2021102.
Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in Western countries but is rare in the East Asian countries. Due to its rarity and the lack of feasible novel agents and laboratory prognostic tools, there are limited data on the clinical outcomes of this disease in Asia. To clarify the current treatment status, we performed a multicenter retrospective analysis of patients with CLL in Korea.
The medical records of 192 eligible patients between 2008 and 2019 were reviewed for clinical characteristics, treatment courses, and outcomes. The first-line treatment regimens of the patients included in this analysis were as follows: fludarabine/cyclophosphamide/ rituximab (FCR) (N=117, 52.7%), obinutuzumab plus chlorambucil (GC) (N=30, 13.5%), and chlorambucil monotherapy (N=24, 10.8%).
The median progression-free survival (PFS) was 55.6 months, and the average 2-year PFS rate was 80.3%. PFS was not significantly different between the patients receiving FCR and those receiving GC; however, chlorambucil treatment was associated with significantly inferior PFS (P <0.001). The median overall survival was 136.3 months, and the average 5- and 10-year OS rates were 82.0% and 57.4%, respectively.
This is one of the largest studies involving Korean patients with CLL. Although the patients had been treated with less favored treatment regimens, the outcomes were not different from those reported in Western studies.
慢性淋巴细胞白血病（CLL）是西方国家最常见的成人白血病类型，但在东亚国家较为罕见。由于其罕见性以及缺乏可行的新型药物和实验室预后工具，亚洲关于该疾病临床结局的数据有限。为阐明当前的治疗状况，我们对韩国的CLL患者进行了多中心回顾性分析。
回顾了2008年至2019年间192例符合条件患者的病历，以了解其临床特征、治疗过程和结局。本分析纳入患者的一线治疗方案如下：氟达拉滨/环磷酰胺/利妥昔单抗（FCR）（n = 117，52.7%）、奥妥珠单抗联合苯丁酸氮芥（GC）（n = 30，13.5%）以及苯丁酸氮芥单药治疗（n = 24，10.8%）。
中位无进展生存期（PFS）为55.6个月，平均2年PFS率为80.3%。接受FCR治疗的患者与接受GC治疗的患者之间的PFS无显著差异；然而，苯丁酸氮芥治疗的PFS显著较差（P <0.001）。中位总生存期为136.3个月，平均5年和10年总生存率分别为82.0%和57.4%。
这是涉及韩国CLL患者的最大规模研究之一。尽管患者接受的是不太理想的治疗方案，但其结局与西方研究报告的结果并无不同。
